Redox Cycling and Mitochondrial Bioenergetic Collapse
Doxorubicin-mediated cardiotoxicity originates from single-electron reduction of its quinone moiety by mitochondrial NADH dehydrogenase (Complex I) and NADPH-dependent oxidoreductases, producing a transient semiquinone radical intermediate [1]. This semiquinone rapidly shifts an electron onto molecular oxygen, yielding continuous fluxes of superoxide anions (O₂^{\bullet-}) and hydrogen peroxide (H₂O₂) while regenerating the parent quinone backbone [1][2]. In the H9c2 rat cardiomyocyte model, this futile redox cycle operates with a Michaelis constant (Km) of approximately 10 to 20 μM, leading to acute respiratory control ratio collapse [1]. Doxorubicin demonstrates stereochemical avidity toward the inner mitochondrial membrane, binding cardiolipin with an association constant (Ka) of 1.6 × 10[6] M^-1 [2]. This stable lipid-drug interaction uncouples oxidative phosphorylation, mobilizes cytochrome c into the intermembrane space, and impairs ATP synthesis [2][3].
Concurrently, doxorubicin forms a ternary cleavage complex with Topoisomerase IIβ (Top2β) in quiescent post-mitotic cardiomyocytes, triggering unrepaired DNA double-strand breaks and transcription factor arrest, a genotoxic signature distinct from Topoisomerase IIα inhibition in rapidly dividing neoplastic cells [2]. Table 1 benchmarks the operational binding kinetics, redox generation metrics, and enzymatic parameters of doxorubicin against reference cardioprotective interventions across preclinical models. The selective retention of doxorubicin within cardiac mitochondria, compounded by limited endogenous catalase and superoxide dismutase activity in cardiomyocytes, shifts intracellular equilibrium toward unchecked oxidative stress [1][3]. These bioenergetic and enzymatic perturbations precede downstream transcriptional alterations, establishing an oxidative microenvironment that directly destabilizes primary cardiomyocyte survival networks.
Biphasic Keap1-Nrf2 Dysregulation and Antioxidant Collapse
The endogenous response to doxorubicin exposure displays biphasic activation-to-repression kinetics centered on the Kelch-like ECH-associated protein 1 (Keap1) and nuclear factor erythroid 2-related factor 2 (Nrf2) axis [3][4]. Under acute, sub-micromolar challenge (0.1–0.3 μM), reactive oxygen species covalently modify sensor cysteines (Cys151, Cys273, Cys288) on Keap1, disrupting Cullin 3 (Cul3)-dependent polyubiquitination and promoting transient Nrf2 nuclear accumulation [3]. Nevertheless, persistent doxorubicin exposure terminates this defensive pathway [4][5]. In C57BL/6 mouse myocardium, extended drug presence induces tripartite motif-containing 21 (TRIM21), an E3 ubiquitin ligase that targets p62/SQSTM1 for proteasomal degradation, thereby freeing Keap1 to sequester and degrade de novo Nrf2 [3].
Parallel post-translational modifications accelerate this transcriptional shutdown. Doxorubicin activates glycogen synthase kinase-3 beta (GSK-3β), which phosphorylates serine residues within the Neh6 domain of Nrf2, creating a degradation motif recognized by the β-TrCP/Cul1 ubiquitin ligase complex independent of Keap1 [4][5]. Concurrently, protein arginine methyltransferase 4 (PRMT4)-dependent methylation of Nrf2 restricts its nuclear translocation capacity [6]. Transcriptional suppression of the Antioxidant Response Element (ARE) battery ensues: expression of the catalytic and modifier subunits of glutamate-cysteine ligase (GCLC, GCLM) and solute carrier family 7 member 11 (SLC7A11, the core antiporter subunit of system Xc⁻) plummets by more than 70% within 48 hours [6][7]. Total intracellular glutathione (GSH) reserves drop below 20% of basal concentrations, leaving the myocardium defenseless against lipid peroxidation [4][7].
Labile Iron Pool Expansion and Ferritinophagy Activation
Disruption of homeostatic iron sequestration constitutes the second obligate event in doxorubicin-induced myocardial pathogenesis [1][7]. Doxorubicin directly perturbs iron-regulatory proteins 1 and 2 (IRP1/2) post-transcriptionally, binding critical hairpin loops in iron-responsive elements (IREs) on target mRNAs [8]. This structural interference drives sustained upregulation of transferrin receptor 1 (TfR1) alongside down-regulation of the primary basolateral iron exporter ferroportin (FPN1), inducing net unidirectional iron influx into cardiac sarcoplasm [1][8]. In primary cardiomyocytes, these transport anomalies escalate basal cytosolic labile iron pool (Fe²⁺) levels three- to five-fold within 24 hours of exposure [1].
Sustained oxidative stress accelerates nuclear receptor coactivator 4 (NCOA4)-mediated autophagic clearance of iron storage complexes, termed ferritinophagy [7][8]. Phosphorylated NCOA4 binds the conserved surface loop of ferritin heavy chain 1 (FTH1) with high affinity, delivering iron-laden ferritin nanocages into acidic autolysosomes for hydrolytic degradation [7]. The subsequent release of unchelated ferrous iron (Fe²⁺) overwhelms residual cytoplasmic chelating proteins [8]. Unrestricted ferrous iron engages in relentless intracellular Fenton cascades (Fe²⁺ + H₂O₂ → Fe³⁺ + ^{\bulletOH + OH^-}), producing hydroxyl radicals whose diffusion distance is limited only by immediate collision with membrane phospholipids [1][8]. In the zebrafish model, genetic suppression of ferritinophagy or pharmacological chelation prevents doxorubicin-mediated iron accumulation and preserves contractile fractional shortening, confirming that unsequestered iron serves as the catalytic driver of cardiomyocyte demise [2].
GPX4 Depletion and Electrophilic 4-HNE Adduct Accrual
The lethal intersection of cellular glutathione depletion and labile iron accumulation manifests as a systemic failure of phospholipid hydroperoxide detoxification [6][8]. Glutathione peroxidase 4 (GPX4), the sole selenoprotein enzyme capable of reducing esterified phospholipid hydroperoxides (PLOOH) to non-toxic lipid alcohols (PLOH) within biological membranes, undergoes dual transcriptional and post-translational elimination [8]. Loss of Nrf2 activity arrests de novo GPX4 transcription, while the direct depletion of its essential cofactor, GSH, renders catalytic selenocysteine (Sec46) vulnerable to irreversible oxidative inactivation [6]. Doxorubicin treatment drives GPX4 enzymatic activity down by >80% in Sprague-Dawley rat ventricular tissue, setting a permissive threshold for lethal lipid autoxidation [9].
Simultaneously, doxorubicin activates acyl-CoA synthetase long-chain family member 4 (ACSL4) and lysophosphatidylcholine acyltransferase 3 (LPCAT3), selectively incorporating polyunsaturated fatty acids (PUFAs)—predominantly arachidonic acid (AA, C20:4) and adrenic acid (AdA, C22:4)—into membrane-bound phosphatidylethanolamines (PE-PUFAs) [6]. Ferrous iron catalyzes radical abstraction of bis-allylic hydrogens from these PE-PUFAs, triggering an autoperoxidative chain reaction that generates toxic phospholipid hydroperoxides (PE-AA-OOH, PE-AdA-OOH) [6][8]. Degradation of these peroxides yields abundant α,β-unsaturated reactive aldehydes, including 4-hydroxynonenal (4-HNE) and malondialdehyde (MDA) [6][9]. Electrophilic 4-HNE forms irreversible covalent Michael adducts with nucleophilic histidine, cysteine, and lysine residues on sarcoplasmic/endoplasmic reticulum Ca²⁺-ATPase 2a (SERCA2a) and cardiac troponin I (cTnI) [9]. These protein-lipid adducts disrupt calcium reuptake kinetics and mechanical tension generation, precipitating systolic left ventricular dysfunction.
Ultrastructural Christolysis and Non-Apoptotic Terminal Rupture
The terminal phase of doxorubicin cardiomyopathy displays morphological and biochemical hallmarks that diverge from canonical apoptosis and receptor-mediated necroptosis [8][9]. Under continuous, clinically relevant doxorubicin exposures (0.1–0.5 μM), dying cardiomyocytes exhibit no canonical genomic DNA cleavage ladders and lack active, cleaved caspase-3 or caspase-9 fragments [8]. Pan-caspase inhibitors, such as z-VAD-FMK, and receptor-interacting protein kinase 1 (RIPK1) inhibitors, such as necrostatin-1, fail to rescue cell viability or halt biomarker release [8][9]. The dominant cell death modality conforming to this pharmacological profile is ferroptosis, driven by unresolved iron-dependent peroxidative destruction of cellular membranes [6][8].
Transmission electron microscopy (TEM) of myocardium from doxorubicin-treated Balb/c mice reveals distinctive organellar lesions: dysmorphic mitochondria featuring outer membrane rupture, widespread disintegration of cristae (christolysis), and electron-dense condensation of the internal matrix, without chromatin marginalization or apoptotic blebbing [6][9]. Pharmacological administration of lipophilic radical-trapping antioxidants (RTAs) such as ferrostatin-1 and liproxstatin-1, or catalytic iron chelators like dexrazoxane and deferoxamine, completely suppresses these ultrastructural abnormalities and restores ejection fraction and fractional shortening [2][6][9]. Similarly, the small-molecule isoflavone tectorigenin restores the p62-Keap1-Nrf2/GPX4 cascade, demonstrating that stabilizing the endogenous antioxidant transcriptional response terminates 4-HNE production and structural christolysis in H9c2 cells [9]. These empirical interventions confirm that doxorubicin-induced cardiotoxicity represents an actionable ferroptotic execution program driven by transcriptional exhaustion of the Nrf2 signaling network.